Hemab Therapeutics Holdings, Inc. (COAG)
D
Pipeline Grade
Financial Position (from SEC Filings)
$49.9M
Cash & Equivalents
$21.6M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$1,776M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-07-01 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06610201 | A Study of Bleeding and Treatment in Participants With Von Willebrand Disease | OTHER | Recruiting | 200 |
| NCT06754852 | A Study Assessing HMB-002 in Participants With Von Willebrand Disease | PHASE2 | Recruiting | 108 |
| NCT07347249 | A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency | PHASE2 | Recruiting | 18 |
| NCT06211634 | A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Gl... | PHASE2 | Active Not Recruiting | 57 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.